As the super-contagious delta variant began to spread widely, scientists at BioNTech, the Germany-based company that partnered with Pfizer to make the first approved COVID-19 vaccine, went into the ...

With the delta variant now dominant in the United States, study results highlight the need for officials to do everything they can to increase vaccine uptake. As the United States grapples with a ...

(Reuters) - The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that have yet to be certified by peer ...

Oct 4 (Reuters) - The effectiveness of the Pfizer Inc (PFE.N), opens new tab/BioNTech SE vaccine in preventing infection by the coronavirus dropped to 47% from 88% six months after the second dose, ...

Adult hospitalizations from Omicron-related SARS-CoV-2 (COVID-19) were less severe than Delta, and the Pfizer-BioNTech vaccine (also known as Comirnaty and BNT162b2) remains effective in preventing ...

New research in nursing home residents found that a third dose of the Pfizer-BioNTech COVID-19 vaccine was effective for at least three months in protecting against the Delta and Omicron variant.